Fig. 14.1 Metastatic cholangiocarcinoma to the liver Fig. 14.2 Retroaortic/retrocaval recurrent cholangiocarcinoma Fig. 14.3 Lytic metastases to the (a) iliac bone and (b) spine Fig. 14.4 Pulmonary metastatic cholangiocarcinoma Pathologic…
Author/institution Proposed expanded criteria Radiology/path 5-year survival Yao, UCSF [14] 1 nodule ≤6.5 cm, or 2–3 nodules ≤4.5 cm and total tumor diameter ≤8 cm Pathology MC—72 % EC—73 %…
Fig. 17.1 Breakdown of etiology of disease leading to liver transplantation, adapted from Singal et al. [1]. Abbreviations: CC cryptogenic cirrhosis, CCLD chronic cholestatic liver disease, HBV hepatitis B virus,…
New waitlist registrants 2004 New waitlist registrants 2013 Percentage increase (%) Hepatitis C 2887 3291 14 Alcoholic liver disease 1400 2024 45 Nonalcoholic fatty liver disease 804 2174 170…
Fig. 16.1 Primary cause of disease in pediatric liver transplant recipients in the United States, 2010–2012 16.2 Primary Hepatic Malignancies The primary liver tumor seen most frequently in children is…
Inclusion criteria Exclusion criteria Confirmed diagnosis of primary sclerosing cholangitis before liver transplantation Hepatic artery thrombosis or stenosis And Chronic ductopenic rejection Cholangiographic evidence of intrahepatic and/or extrahepatic biliary stricturing,…
Authors # of transplant recipients Total cases with pre-transplant malignancies # of recurrences post-transplant Type of cancer and pre-transplant time Post-transplant recurrence time Treatment Last follow-up post-recurrence Kelley et al….
Authors (references) No. of patients HBV DNA positive at LT (%) Prevention of HBV recurrence Follow-up (months) HBV recurrence N (%) Risk factors for HBV recurrence HBIG regimen Antiviral Indefinite…
Author Year n LRT Inclusion criteria for DS protocol Successful DS criteria Mandatory waiting time prior to LT (months) The role of AFP DS rate LT (patients) Waiting time to…
1. Liver transplant for autoimmune hepatitis 2. Autoantibodies (anti-nuclear, anti-smooth muscle or anti-liver kidney microsomal) in significant titer (>1:40) 3. Sustained rise (above twice normal of levels) of serum aminotransferase…
